Theranostic Layer‐by‐Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing. (7th January 2020)

• Record Type: Journal Article
• Authors: Boehnke, Natalie; Correa, Santiago; Hao, Liangliang; Wang, Wade; Straehla, Joelle P.; Bhatia, Sangeeta N.; Hammond, Paula T.
• Is Part Of: Angewandte Chemie. Volume 132:Number 7(2020)
• Page Start: 2798
• Page End: 2805
• Publication Date: 2020-01-07
• Subjects: Gen-Übertragung -- Nanopartikel -- Schichtweiser Aufbau -- Selbstassemblierung -- Theranostik; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.201911762
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Layer‐by‐layer nanoparticles (NPs) are modular drug delivery vehicles that incorporate multiple functional materials through sequential deposition of polyelectrolytes onto charged nanoparticle cores. Herein, we combined the multicomponent features and tumor targeting capabilities of layer‐by‐layer assembly with functional biosensing peptides to create a new class of nanotheranostics. These NPs encapsulate a high weight percentage of siRNA while also carrying a synthetic biosensing peptide on the surface that is cleaved into a urinary reporter upon exposure to specific proteases overexpressed in the tumor microenvironment. Importantly, this biosensor reports back on a molecular signature characteristic to metastatic tumors and associated with poor prognosis, MMP9 protease overexpression. This nanotheranostic mediates noninvasive urinary‐based diagnostics in mouse models of three different cancers with simultaneous gene silencing in flank and metastatic mouse models of ovarian cancer. Abstract : Schichtarbeit : Eine neue Art der Nanotheranostik wurde durch die Kombination von Mehrkomponenten‐Eigenschaften und Tumor‐Targeting‐Fähigkeiten einer schichtweisen Anordnung funktionaler Biosensor‐Peptide entwickelt. siRNA‐beladene Nanopartikel, die mit einem synthetischen Peptid funktionalisiert sind, das in der Lage ist, MMP9‐Überexpression in der Tumor‐Mikroumgebung zu überwachen, vermittelt nicht‐invasive Urin‐basierte Diagnostik sowie Gen‐Silencing.